US FDA approves over-the-counter Tylenol combination pill for pain relief
The US FDA has approved the first over-the-counter combination of acetaminophen and naproxen sodium for extended pain relief.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
📍 How it ended
The FDA approved the first over-the-counter acetaminophen-naproxen combination pill for pain relief in individuals ages 12 and older. The approval provided a lift to Kenvue's stock despite pushback from the Trump administration.
Epilogue added 113d ago, after coverage quieted.
The brief
The United States Food and Drug Administration (FDA) has granted approval for a new over-the-counter pain relief medication combining Tylenol with naproxen. According to a statement from Kenvue, this is the first and only over-the-counter fixed-dose combination available to consumers. The specific formulation of the tablet consists of 650 mg of acetaminophen and 220 mg of naproxen sodium. As detailed by Contemporary Pediatrics and other outlets, the medication is approved for use in individuals who are 12 years of age and older. The primary objective of this combination is to provide users with pain relief for up to 12 hours. Coverage of this approval is widespread, appearing in reports from Reuters, USA Today, and several local affiliates including WTHR, WFAA, 10TV, and cbs8.com.
Industry-specific publications such as Pharmacy Times and Consultant360 emphasize that this represents the first time an acetaminophen-naproxen combination has been cleared for over-the-counter sale. Kenvue, the company behind the product, has officially confirmed the dosing and the specific drug components involved in the fixed-dose tablet. These outlets collectively highlight the shift toward combining two widely used pain medications into a single delivery method for the consumer. From a business perspective, Yahoo Finance reports that Kenvue (KVUE) saw its stock price rise following the FDA's decision. However, the financial analysis from Yahoo Finance Singapore suggests that the company's valuation remains tight. Another critical piece of context provided by Yahoo Finance is that the FDA approval proceeded despite pushback from the Trump administration.
This indicates a point of friction between regulatory decisions and the current political executive branch, adding a layer of complexity to the product's market entry and the company's current financial standing. Moving forward, the focus will likely be on the commercial rollout of the Tylenol with naproxen combination. Observers will be watching how Kenvue manages its valuation in light of the stock rise and the ongoing pushback from the Trump administration mentioned in the coverage. Because the drug is now approved for those 12 and older, the market will monitor the adoption rate of this 12-hour pain relief option compared to existing single-ingredient over-the-counter medications. The availability of this first-of-its-kind fixed-dose combination marks a new development in the accessible pain management landscape.
Synthesized by PULSE from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 115d ago.
Quick answers
What are the active ingredients and dosages in the new Tylenol combination pill?
The pill contains 650 mg of acetaminophen and 220 mg of naproxen sodium.
Who is eligible to use this new medication?
The FDA has approved the acetaminophen-naproxen sodium combination tablet for individuals ages 12 and older.
How long is the pain relief expected to last?
The medication is designed to provide pain relief for up to 12 hours.
Coverage (15)
- Tylenol With Naproxen FDA Approval Could Be A Game Changer For Kenvue (KVUE) Yahoo Finance · 116d ago
- FDA approves new over-the-counter pain relief WSOC TV · 116d ago
- FDA approves over-the-counter Tylenol with naproxen combination WKYC · 116d ago
- FDA Approves First OTC Acetaminophen–Naproxen Combination for 12-Hour Pain Relief Pharmacy Times · 116d ago
- FDA approves over-the-counter Tylenol with naproxen combination WTHR · 116d ago
- Kenvue (KVUE) Gets An FDA Lift On Tylenol As Valuation Looks Tight Yahoo Finance Singapore · 116d ago
- FDA approves over-the-counter Tylenol with naproxen combination cbs8.com · 116d ago
- FDA approves over-the-counter Tylenol with naproxen combination WFAA · 116d ago
- KVUE Stock Rises As FDA Approves Tylenol Combination Despite Trump Administration’s Pushback Yahoo Finance · 116d ago
- FDA approves over-the-counter Tylenol with naproxen combination 10TV · 116d ago
- FDA approves acetaminophen-naproxen sodium combination tablet for ages 12 and older Contemporary Pediatrics · 116d ago
- FDA Approves First OTC Acetaminophen–Naproxen Combination for Up to 12 Hours of Pain Relief Consultant360 · 116d ago
- FDA approves Tylenol® with Naproxen, the first and only over-the-counter fixed-dose combination of acetaminophen (650 mg) and naproxen sodium (220 mg) Kenvue · 116d ago
- Two pain drugs used by millions will be combined in a single tablet USA Today · 116d ago
- US FDA approves over-the-counter Tylenol combination pill for pain relief Reuters · 116d ago
Topics
Related trends
The first pill to slow Alzheimer’s could come from an unexpected place
An experimental oral Alzheimer's drug derived from an unexpected medical category shows varied results in phase 3 clinical trials.
Roche Secures First U.S. Approval for New Breast-Cancer Pill
Roche wins FDA approval for its first U.S. oral SERD, giredestrant plus everolimus, for hormone-resistant advanced breast cancer.
Novo says Wegovy injection lowers BMI and obesity rates in children in trial
Novo Nordisk reports Wegovy injection reduced BMI and obesity rates in children as young as six in a clinical trial, expanding the drug's potential pediatric use.
The GLP-1 boom has a dark side
FDA orders new eye-risk warnings on a dozen GLP-1 drugs, including Ozempic and Zepbound, amid reports of vision-threatening events.
Millions of Americans are not taking their GLP-1 drugs as prescribed
Nearly half of U.S. GLP-1 users are altering prescribed dosing, with cost and side effects driving widespread non-adherence.
FDA rejects Summit’s ivonescimab, derailing US arrival of much-hyped PD-1xVEGF class
The United States Food and Drug Administration has rejected Summit Therapeutics and Akeso's lung cancer drug ivonescimab.